November 12, 2013
11:30 am to 12:30 pm EST

Sponsored by
Quanterix
 

Symposium Course Description:

The percentage of babies born from Assisted Reproduction Techniques or In Vitro Fertilization in many countries is now between 2%-6%. One major issue is that many of the pregnancies are twins or triplets, which can lead to complications for both the mother and infants. The twins and triplets occur because multiple embryos are created using these procedures and 2 or more embryos are replaced back to the mother so as to increase the chances of pregnancy. Being able to identify which single embryo is the one that will lead to a pregnancy would allow us to safely transfer one embryo. During In Vitro Fertilization embryos are grown individually in small microliter droplets of culture media for several days and produce numerous factors which if diagnosed could provide information as to which individual embryo was the most viable. The Single Molecule Array (Simoa) technology and its ability to quantify low abundance protein biomarkers may provide the non-invasive assay capable of identifying these individual embryos.

Learning Objectives:


  • Understand Single Molecule Array (Simoa) technology and its application for basic, translational and clinical researchers who wish to quantify and validate low abundance protein biomarkers.

Who Will Benefit:


  • Clinical and Research laboratories seeking technologies aimed at discriminating candidate proteins present at very low concentrations and in very small volumes
  • Scientists seeking state of the art diagnostic technology capabilities and biomarker researchers seeking areas for implementation of their biomarkers

Program Agenda: 

1. Immunoassays in Multiplex for Biomarker Discovery and Validation (35 min) - Presentation by Dr. Denny Sakkas, Boston IVF

2. Introduction to Quanterix Single Molecule Array (Simoa) technology (15 min) - Presentation by Dr. David Duffy, Quanterix Corporation

3. Q&A (5-10 min)


Speaker Information:


Denny Sakkas, Ph.D.
Scientific Director
Boston IVF

David Duffy, Ph.D.
Vice President, Research and Chief Technology Officer
Quanterix Corporatio